News and Trends 3 May 2018 World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […] May 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 2 May 2018 Combining Liquid Biopsy and Artificial Intelligence to Outrun Cancer Making liquid biopsy and artificial intelligence technologies work together could help doctors make faster decisions to treat cancer on time. Philip talked to the CEO of Cambridge Cancer Genomics to find out what this approach can mean for the treatment of cancer. Although much progress has been made in recent years, cancer remains one of […] May 2, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […] April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Apr 2018 The 5 Best-Selling European Drugs of 2017 Biologicals have completely changed the way we treat diseases, and their growth has exploded in the last two decades. Not surprisingly, they took a whopping 7 out of 15 spots on the list of 2017’s best selling drugs globally. We were of course keen to find out how European-derived drugs faired out in this list. […] April 30, 2018 - 7 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
Startup Scout 27 Apr 2018 This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test Today, we’re in Matosinhos, Portugal, visiting FASTinov, a biotech that is developing an antimicrobial susceptibility test that are faster than standard assays. The technology could help battle antibiotic resistance by identifying appropriate treatments. Mission: Founded in 2013, FASTinov is developing a new type of test for antimicrobial susceptibility that can help combat the global health problem of antibiotic […] April 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2018 Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US Pluristem Therapeutics will start a Phase III trial this year in the US for its pioneering cell therapy that uses placenta cells to restore muscle injuries. Pluristem Therapeutics, an Israeli biotech and world-leader in cell therapies, has received a green light from the FDA to start a Phase III study in the US. The trial will test […] April 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2018 Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […] April 25, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2018 Planting the Seeds to Grow the Italian Biotech Industry Many European countries, including the UK, France, Germany, and Switzerland, boast a thriving biotech industry. Others are still a step behind when it comes to industrializing their research. Let’s take a look at how Italy is pushing through to make it to the first league. Italy is certainly a pioneer and leader in life science research — […] April 25, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 Fundraising Boosts Italian Red Blood Cell Therapy EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 New Class of Antibiotics Combats the Three Deadliest Bacteria in the World A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2018 Can DIY Biology Ever Become a Big Player in Biotech? Alongside university research and industry R&D, a third, parallel community actively uses tools and methods of the life sciences: biohackers. What are they, and what is their impact on biotech and the startup scene? One of the richest persons alive and one of the first hackers ever, Bill Gates, said that if he were young today […] April 24, 2018 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2018 The First CAR-T Therapy Is Not Living Up to Commercial Expectations Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […] April 23, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email